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Abstract
Purpose of Review Dengue is found in tropics and subtropics that are considered to be popular travel destinations. We set out to
review the burden of dengue on international travelers.
Recent Findings GeoSentinel, a global network of travel medicine providers, has seen an increasing trend of dengue in returning
travelers over the past decades. In Southeast Asia, annual proportionate morbidity increased from 50 dengue cases per 1000 ill-
returned travelers in non-epidemic years to an average of 159 cases per 1000 travelers during epidemic years. Dengue is the
leading cause of fever in returning travelers, having overtaken malaria for travelers to Southeast Asia. Most dengue seroconver-
sion studies in travelers report an attack rate of around 5% depending on duration of travel and destination.
Summary Dengue vaccination would be justified for travelers. The first licensed dengue vaccine CYD-TDV is only recom-
mended in seropositive individuals. This review considers preventive measures including how best to use the first licensed
dengue vaccine CYD-TDV.
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Background
Dengue virus has become the world’s most frequent
Flavivirus. Transmitted by mosquitoes of the genus Aedes,
dengue is found mainly in the tropics and subtropics [1, 2•]
that are considered to be popular travel destinations [3].
Understanding the extent of risk of dengue in travelers is im-
portant for travelers, clinicians, and travel medicine providers.
Pre-travel advice will need to consider the epidemiology of
dengue, attack rates in travelers, host factors, and preventive
measures. Clinicians caring for ill-returned travelers should be
able to recognize dengue and be familiar with its management.
Dengue infections exhibit a dynamic risk, with strong geo-
graphical heterogeneities, hence we need to improve the ac-
curacy of risk communication combined with appropriate pre-
ventive measures [4••].
As surveillance is often just passive with mandatory
dengue notifications based on illness clinically compatible
with dengue often without laboratory confirmation, the
true incidence is not known [5]. Modeling combined with
cartographic approaches have estimated the annual inci-
dence of dengue infections to be 400 million infections
per year, with clinically apparent cases representing about
25% of all dengue virus infections [6]. However, dengue
incidence is cyclical often with a 3–5-year pattern [7] and
the incidence is far lower in non-epidemic years. Asia
accounts for 75% of the dengue disease burden, followed
by Latin America and Africa [6]. In highly endemic areas,
approximately 10% of all febrile episodes are due to den-
gue [8••].
The rapid geographic spread of dengue viruses globally is
the result of increasing mobility of people via modern means
of transportation [9–12]. Air travel connectivity between
dengue-endemic countries and from dengue-endemic coun-
tries to non-endemic, but still vulnerable settings has increased
exponentially [3]. While imported dengue cases to the USA
have resulted in small dengue clusters for many years [13], the
first autochthonous sporadic cases in Europe (France and
Croatia) were reported only in 2010 [14, 15]. In 2012, the first
major European outbreak of dengue occurred inMadeira [16].
Viremic travelers to non-endemic areas where Aedes
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mosquitoes exist constitute the source for triggering autoch-
thonous transmission [17••, 18]. About 36% of travelers who
acquired dengue during their travel to dengue-endemic coun-
tries returned to Europe during the acute phase of the infection
(up to 7 days after symptom onset), and 58% of travelers with
an acute dengue infection were viremic when seeking medical
care, thus highlighting the potential for dengue virus introduc-
tion [19]. Fortunately, the seasonal window in Europe when
vectorial capacity is sufficient to sustain autochthonous trans-
mission is short [20••]. The risk of dengue importation that
will lead to establishment in temperate climates such as those
in Europe was modeled to be very low [17••].
The principal vector Aedes aegypti is a peri-domiciliary
day-biting mosquito capable of biting several people in a short
period of time. Aedes albopictus, although a less efficient
vector compared to Aedes aegypti, is continuing its geograph-
ic expansion into tropical and temperate climates. Climate
change with global warming facilitates a wider geographic
distribution of Aedes mosquitoes, thereby increasing dengue-
epidemic potential in temperate regions. [21] Dengue caused
an outbreak in the temperate climate of Japan in 2013 due to
increasing importation via travelers from China [22].
Travelers have often served as a sentinel to unmask ongoing
dengue transmission in countries before national authorities
notified the outbreak [12, 23].
Risk of Dengue in Travelers
In parallel with the increasing incidence of dengue globally,
the incidence of dengue in travelers has increased exponen-
tially in the past decades [24, 25]. GeoSentinel is a global
network of travel medicine providers that see ill-returning
travelers [26]. GeoSentinel has seen an increasing trend of
dengue in returning travelers over the past decades [27, 28].
In Southeast Asia, annual proportionate morbidity increased
from 50 dengue cases per 1000 ill-returned travelers in non-
epidemic years to an average of 159 cases per 1000 travelers
during epidemic years [29]. Dengue is the leading cause of
fever in returning travelers, having overtaken malaria for trav-
elers to Southeast Asia [29]. GeoSentinel also identified the
seasonality of dengue transmission [29]. Dengue occurs both
in adult [29, 30] and pediatric travelers [31, 32], with one
study in expats showing similar attack rates for adults
(4.7%) and children (6.3%) [33]. However, as most travelers
are adults, the majority of travel-associated dengue cases have
been reported in adult travelers.
Prospective studies are better suited to determine the attack
rate than sentinel surveillance. A dengue antibody seroconver-
sion study in travelers with amedian length of travel of 21 days
seen in the Boston Area Travel Medicine Network found a
seroconversion rate by either anti-DENV IgM or IgG ELISA
between 2.9 and 6.8% [34]. Eighteen percent of those
with seroconversion reported dengue-like symptoms.
Seroconversion was documented for travel to Africa as well
as countries and regions known to be highly dengue endemic
(India, Brazil, Southeast Asia) [34]. In Swedish travelers, an
increasing trend of dengue infections over time was found for
most destinations [35•]. The majority of the dengue cases
were acquired in Thailand (492 out of 925 travelers; 53%),
with an attack rate of 13.6 (95% CI 12.7, 14.4) per 100,000
travelers. However, the two highest attack rates per 100,000
travelers were found for Sri Lanka (45.3, 95% CI 34.3, 56.4)
and Bangladesh (42.6, 95% CI 23.8, 61.5).
Prevalence of dengue virus infection in US travelers who
have lived in or traveled to dengue-endemic countries was
19%; 12% had antibodies by PRNT, 85% of whom had no
history of dengue [36]. Presence of DENV antibodies was
associated with years lived in dengue-endemic countries and
self-reported history of dengue [36]. 5.8% of travelers
returning to Italy had IgM and/or IgG antibodies specific for
dengue [37]. The seroprevalence of dengue infection in one
Australian study in travelers to Asia was 4.4% and a greater
number of prior trips to Asia was a predictor for dengue sero-
positivity [38]. Dengue was the most common laboratory-
confirmed diagnosis in travelers from Bali, reported in 5%
of travelers returning to Australia [39].
Special Sub-Populations of Travelers
Peace Corps Volunteers (and other humanitarian aid workers
as well as missionaries) are often long-term travelers at partic-
ular risk for dengue. The dengue incidence rate was 1.12 cases
per 1000 volunteer-months [40]. The highest rate of dengue
among volunteers was reported in the Caribbean region, with
a rate of 5.51 cases per 1000 volunteer-months followed by
the East Asia/South Asia region (3.34) and Central America
(2.55) [40]. Recent or past infection with a DENVwas evident
in 93% missionaries with available sera, but the sample size
was very small to defer such a high prevalence for all mission-
aries [41]. In a serosurveillance project using predeployment
and postdeployment sera collected from US Army Special
Operations Forces deployed to South and Central America,
Africa, and Southeast Asia showed a 13.2% seropositivity rate
[42]. Business travelers are another risk group as discussed in
a recent GeoSentinel analysis [43]. Given the fact that dengue
is predominantly a disease of urbanized areas [44•], even
short-term travel for business in cities may pose a risk.
Longer-term expats were shown to be at higher risk than the
endemic population [33]. Despite increasing migration to
Europe [45] and South-South migration and travel [46–48],
little is known about the incidence of dengue in migrants [49,
50]. In Singapore, differences were documented for dengue
severity between local and migrant Chinese [42]. In migrants
now living in non-endemic countries, returning to dengue-
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endemic countries to visit friends and relatives (VFR), a
higher risk of severe dengue was documented in a
GeoSentinel study [51], which was most likely due to the fact
that many of the VFRs already had a primary dengue infection
and were hence at a higher risk of a more severe dengue.
Travelers visiting friends and relatives (VFRs) often have
complex pre-travel needs. Future research should focus on
improving the uptake of recommended interventions in VFR
travelers [52]. Given the rise of migrants especially to Europe,
with importation of dengue and other infectious diseases, cli-
nicians need to be aware of dengue, and surveillance of
imported dengue via migrants would be justified especially
for migrants from Southeast Asia and Latin America.
Clinical Manifestations and Complications
of Dengue
In most cases, dengue is a self-limiting febrile illness with
spontaneous recovery, and no interventions are needed.
Clinically relevant complications develop in a proportion of
these patients however, with systemic vascular leak syndrome
being the predominant complication with or without hemor-
rhages [53]. This vasculopathy is characterized by increased
vascular permeability, plasma leakage, and intravascular vol-
ume depletion, which may progress to life-threatening dengue
shock syndrome [54, 55]. The 2009 WHO dengue case clas-
sification now identifies symptomatic individuals as having
“dengue” if they have no major complications, while those
who experience complications in any of three categories, (a)
plasma leakage severe enough to cause shock or respiratory
distress, or (b) severe bleeding, or (c) severe organ impair-
ment, are designated as having “severe dengue” [53]. There
is a strong epidemiological association between development
of severe complications and secondary infection [56].
Antibody dependent enhancement has been widely used to
explain this phenomenon, but was only recently demonstrated
in clinical epidemiological studies [57••]: progression to se-
vere dengue appears to require certain antibody-to-virus ratios
[57••, 58••]. However, although vascular leakage is the hall-
mark of severe dengue, other unusual severe complications
can also occur. Unusual complications include the
hemophagocytic syndrome [59], myocarditis [60], other car-
diac problems [60–62], and fulminant hepatitis [63].
Complications in the eye may also occur [64]. Neuro-
ophthalmological complications usually involve the posterior
segment and include visual disturbance secondary to retinal
vasculopathy and optic neuropathy [65]. Dengue can manifest
with a wide range of neurological features, which have been
noted in 0.5–21% of patients with dengue admitted to hospital
[65]. Although the association of Zika with Guillain-Barre
syndrome in travelers is much stronger [66•], several cases
of Guillain-Barre syndrome have also been reported to be
associated with dengue [67–73]. Cases of rhabdomyolysis
[74], abducens nerve palsy [75], optic neuritis [76], and
strokes, especially hemorrhagic stroke symptoms have been
reported because of the coagulopathy associated with dengue
fever [77]. Acute encephalopathy is the most common neuro-
logical disorder associated with dengue [78]. Encephalitis is
secondary to the direct central nervous system invasion of the
virus and has also been reported for dengue [78].
Host Factors Relevant for Travelers
Many travelers are older adults, and older travelers may have
more comorbidities [79, 80]. Diabetes has been identified as a
risk factor for dengue, and so have other comorbidities such as
hypertension, cardiovascular disease, and asthma [81, 82].
Travelers with sickle cell disease are thought to be at increased
risk of severe dengue [83]. Pregnant women are another group
at high risk for severe disease, especially during the third
trimester [84, 85], and perinatal transmission to infants is rec-
ognized [86].
Dengue Diagnosis in Travelers
The choice of laboratory test depends on the time since onset
of fever. Before day 5 of illness, during the febrile period,
dengue infections may be diagnosed by virus isolation, by
nucleic acid amplification tests such as reverse transcriptase-
polymerase chain reaction (RT-PCR), or by detection of viral
antigens such as the dengue non-structural protein 1 (NS1) by
enzyme-linked immunosorbent assay (ELISA) or rapid diag-
nostic tests (RDTs). After days 4–5, dengue viruses and anti-
gens disappear from the blood coincident with the appearance
of dengue-specific antibodies, hence serological assays should
be used [87••]. RT-PCR on specimens other than blood (urine
and saliva) [88] can prolong the diagnostic window and is
particularly relevant for confirming the diagnosis in returning
travelers.
While rapid diagnostic tests are available for NS1 antigen
or IgM antibody detection or both simultaneously, the sensi-
tivities and specificities of the available tests are lower than the
equivalent laboratory-based ELISA assays [89]. Nevertheless,
the combination of NS1 antigen and IgM testing at point of
care offers a longer diagnostic window, and RDTs are hence
increasingly being used. NS1 antigen testing has been shown
to be highly specific in travelers [90]. Diagnostic requests for
both Zika virus (ZIKV) and dengue virus (DENV) infections
in returning travelers have significantly increased during the
recent ZIKV outbreak in the Americás [91]. As these
flaviviruses have overlapping clinical syndromes and geo-
graphical distribution, diagnostic differentiation is important
because of different clinical consequences. As flaviviruses are
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known to have a short-viremic period, diagnostics often rely
on serological methods, which are challenging due to exten-
sive cross-reactive antibodies. Although the DENV NS1 anti-
gen assay was highly specific for laboratory confirmed ZIKV-
infected travelers, high percentages of cross-reactivity of
DENV IgM and IgG ELISÁs were found, of which diagnostic
laboratories should be aware [91]. An algorithm for ZIKV
serodiagnosis based on three simple ELISAs has been pro-
posed to distinguish dengue from Zika [92].
The most urgent need is to identify biomarkers that can
help discriminate patients who will progress to a more severe
dengue. However, no single biomarker or combination of bio-
markers have been identified to date, despite substantial ef-
forts to this end [93].
Clinical Management
The mainstay of clinical management is prompt and appropri-
ate rehydration therapy, avoiding both too little as well as too
much fluid. A state-of-the-art review was recently published
in the Lancet Clinical Seminar series [94]. The case fatality
rates under good case management should be below 1% for
symptomatic dengue. Travel medicine providers caring for
dengue patients need to be familiar with the clinical manage-
ment through specialized training [95], and training in travel
and tropical medicine needs to be increasingly incorporated
into undergraduate curricula [96].
Preventive Measures and Vaccination
Personal protective measures for travelers include measures
taken mainly during the day to avoid mosquito bites such as
repellents, long-sleeves and light clothing, and coils or other
vapors [24]. Picaridin-containing repellents appears to be as
effective as DEET (at 30%), but at > 50% DEET seems to be
more effective [97]. However, compliancewith suchmeasures
have been found to be low in travelers [98]. Bed nets are of
limited use as Aedes mosquitoes mainly bite during the day.
Impregnated clothing has been suggested to be effective [99,
100], but this was not proven in a community-based trial
[101]. Wolbachia as a novel vector control strategy was found
to reduce outbreaks as a result of dengue importation in
Northern Australia [102].
Given the overall lack of effective preventive measures,
combined with the relatively high incidence of dengue in trav-
elers, dengue vaccination would be indicated [103]. In 2015,
the first dengue vaccine was licensed. CYD-TDV is a live
attenuated tetravalent vaccine with yellow fever 17D virus
as backbone. In the age group of 9 years and above, efficacy
against hospitalized dengue and severe dengue was high, 83
and 91% respectively [104]. Subsequently, in the year 2017,
new long-term safety data were released which showed that
the vaccine had a different performance depending on
serostatus [105]. The analyses stratified by serostatus showed
an increased risk of severe dengue in those seronegative at
baseline, a risk that emerged about 30 months after the first
dose regardless of age. The most plausible hypothesis is that
the live attenuated CYD-TDV initiates a first immune re-
sponse to dengue in seronegative persons that predisposes
them to a higher risk of severe disease when they experience
their next natural dengue infection [106]. The revised WHO
recommendations in 2018 state that CYD-TDV vaccination is
only recommended in seropositive individuals where the vac-
cine is efficacious and safe [87••]. Serostatus, reflecting
whether or not the individual has experienced a dengue infec-
tion in the past, is determined by a serological assay. As trav-
elers with previous travel to dengue-endemic countries will be
more likely seropositive; screening will therefore need to be
prioritized for travelers according to the extent of previous
exposure to dengue [107••]. The specificity of a serological
assay will depend on the extent of exposure to other
flaviviruses such as Zika, West Nile, tick-borne Encephalitis
(TBE), Japanese encephalitis, (JE) yellow fever (YF) viruses,
and others, or vaccination with Flavivirus vaccines [108]. The
efficacy trials were done with a three-dose schedule, 6 months
apart, which will make completion of the primary schedule
prior to travel unfeasible. However, the vaccine efficacy be-
tween the first and second dose and second and third doses
was similar to the vaccine efficacy after the third dose, in the
overall trial population in the multi-center phase 3 trials [109].
Although no long-term efficacy data for one or two dose
schedules exist because the completion rate of three doses
was very high in the trials, it could be argued that a single
dose prior to travel may suffice in those traveling for less than
6 months [107••].
Besides CYD-TDV, two other chimeric live attenuated
dengue vaccines are now in the phase 3 trials. Whether these
second-generation dengue vaccines will encounter the same
safety issue in seronegative vaccines is unknown. The first
read-outs of the trials will most likely be available by mid-
2019.
Concluding Remarks
Dengue infection in international travelers is not infrequent
and may be associated with substantial morbidity and unde-
sired interruption of travel. Given widespread risk of dengue,
travel medicine counseling should include information on the
risk of dengue in endemic areas and advice on preventing
insect bites and seeking prompt medical attention for febrile
illness. The first licensed dengue vaccine CYD-TDV could be
considered in laboratory-confirmed seropositive travelers;
however, it is not yet licensed in most countries. Good risk
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maps are needed to provide evidence-informed advice on at
risk destinations, such as those published by the Centers for
Disease Control, USA [4••]. Graded evidence for best prac-
tices [110] will be needed for both pre-travel advice and clin-
ical management of travelers with dengue.
Compliance with Ethical Standards
Conflict of Interest The author declares that she has no conflict of
interest.
Human and Animal Rights and Informed Consent This article does not
contain any studies with human or animal subjects performed by any of
the authors.
Disclaimer AWS is consultant to the World Health Organization. The
author alone is responsible for the views expressed in this publication, and
her views do not necessarily represent the decisions or policies of the
World Health Organization.
References
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Kraemer MU, Sinka ME, Duda KA, Mylne AQ, Shearer FM,
Barker CM, et al. The global distribution of the arbovirus vectors
Aedes aegypti and Ae. albopictus. Elife. 2015;4:e08347.
2.• Wilder-Smith A, Gubler DJ, Weaver SC, Monath TP, Heymann
DL, Scott TW. Epidemic arboviral diseases: priorities for research
and public health. Lancet Infect Dis. 2017;17(3):e101–e6 elabo-
rates on reasons for the emergence of Aedes-transmitted
diseases.
3. Glaesser D, Kester J, Paulose H, Alizadeh A, Valentin B. Global
travel patterns: an overview. J Travel Med. 2017;24(4).
4.•• Jentes ES, Lash RR, Johansson MA, Sharp TM, Henry R, Brady
OJ, et al. Evidence-based risk assessment and communication: a
new global dengue-risk map for travellers and clinicians. J Travel
Med. 2016;23(6). Provides a new approach to dengue risk
mapping.
5. Tissera H, Amarasinghe A, Gunasena S, DeSilva AD, Yee LW,
Sessions O, et al. Laboratory-enhanced dengue sentinel surveil-
lance in Colombo District, Sri Lanka: 2012-2014. PLoS Negl
Trop Dis. 2016;10(2):e0004477.
6. Bhatt S, Gething PW, Brady OJ, Messina JP, Farlow AW, Moyes
CL, et al. The global distribution and burden of dengue. Nature.
2013;496(7446):504–7.
7. Earnest A, Tan SB,Wilder-Smith A.Meteorological factors and El
Nino southern oscillation are independently associated with den-
gue infections. Epidemiol Infect. 2012;140(7):1244–51.
8.•• L'Azou M, Moureau A, Sarti E, Nealon J, Zambrano B, Wartel
TA, et al. Symptomatic dengue in children in 10 Asian and Latin
American countries. N Engl J Med. 2016;374(12):1155–66
Provides detailed information on incidence of dengue in
children.
9. Huang Z, Das A, Qiu Y, Tatem AJ. Web-based GIS: the vector-
borne disease airline importation risk (VBD-AIR) tool. Int J
Health Geogr. 2012;11:33.
10. Lopez LF, Amaku M, Coutinho FA, Quam M, Burattini MN,
Struchiner CJ, et al. Modeling importations and exportations of
infectious diseases via travelers. Bull Math Biol. 2016;78(2):185–
209.
11. Quam MB, Khan K, Sears J, Hu W, Rocklov J, Wilder-Smith A.
Estimating air travel-associated importations of dengue virus into
Italy. J Travel Med. 2015;22(3):186–93.
12. Sessions OM, Khan K, Hou Y, Meltzer E, Quam M, Schwartz E,
et al. Exploring the origin and potential for spread of the 2013
dengue outbreak in Luanda, Angola. Glob Health Action.
2013;6:21822.
13. Adalja AA, Sell TK, Bouri N, Franco C. Lessons learned during
dengue outbreaks in the United States, 2001-2011. Emerg Infect
Dis. 2012;18(4):608–14.
14. La Ruche G, Souares Y, Armengaud A, Peloux-Petiot F, Delaunay
P, Despres P, et al. First two autochthonous dengue virus infections
in metropolitan France, September 2010. Euro Surveill.
2010;15(39):19676.
15. Gjenero-Margan I, Aleraj B, Krajcar D, Lesnikar V, Klobucar A,
Pem-Novosel I, et al. Autochthonous dengue fever in Croatia,
August–September 2010. Euro Surveill. 2011;16(9).
16. Wilder-Smith A, Quam M, Sessions O, Rocklov J, Liu-
Helmersson J, Franco L, et al. The 2012 dengue outbreak in
Madeira: exploring the origins. Euro Surveill. 2014;19(8):20718.
17.•• Massad E, Amaku M, Coutinho FAB, Struchiner CJ, Burattini
MN, Khan K, et al. Estimating the probability of dengue virus
introduction and secondary autochthonous cases in Europe. Sci
Rep. 2018;8(1):4629 Novel modeling approaches were used to
estimate the threat of dengue to Europe.
18. Cnops L, Franco L, VanMeensel B, Van den Ende J, Paz Sanchez-
Seco M, Van Esbroeck M. Three cases of imported dengue virus
infection from Madeira to Belgium, 2012. J Travel Med.
2014;21(5):344–8.
19. Neumayr A,Munoz J, SchunkM, Bottieau E, Cramer J, Calleri G,
et al. Sentinel surveillance of imported dengue via travellers to
Europe 2012 to 2014: TropNet data from the DengueTools
Research Initiative. Euro Surveill. 2017;22(1).
20.•• Liu-Helmersson J, Quam M, Wilder-Smith A, Stenlund H, Ebi K,
Massad E, et al. Climate change and Aedes vectors: 21st century
projections for dengue transmission in Europe. EBioMedicine.
2016;7:267–77 Highlights the risk of further spread of Aedes
to Europe.
21. Rocklov J, Quam MB, Sudre B, German M, Kraemer MU, Brady
O, et al. Assessing seasonal risks for the introduction and
mosquito-borne spread of Zika virus in Europe. EBioMedicine.
2016;9:250–6.
22. QuamMB, Sessions O, Kamaraj US, Rocklov J, Wilder-Smith A.
Dissecting Japan’s dengue outbreak in 2014. Am J TropMedHyg.
2016;94(2):409–12.
23. Schwartz E,Meltzer E, MendelsonM, Tooke A, Steiner F, Gautret
P, et al. Detection on four continents of dengue fever cases related
to an ongoing outbreak in Luanda, Angola, March to May 2013.
Euro Surveill. 2013;18(21).
24. Wilder-Smith A, Schwartz E. Dengue in travelers. N Engl J Med.
2005;353(9):924–32.
25. Wilder-Smith A, Gubler DJ. Geographic expansion of dengue: the
impact of international travel. Med Clin North Am. 2008;92(6):
1377–90 x.
26. Freedman DO, Kozarsky PE, Weld LH, Cetron MS. GeoSentinel:
the global emerging infections sentinel network of the
International Society of Travel Medicine. J Travel Med.
1999;6(2):94–8.
27. McCarthy AE, Weld LH, Barnett ED, So H, Coyle C, Greenaway
C, et al. Spectrum of illness in international migrants seen at
GeoSentinel clinics in 1997-2009, part 2: migrants resettled
Curr Infect Dis Rep           (2018) 20:50 Page 5 of 8    50 
internationally and evaluated for specific health concerns. Clin
Infect Dis. 2013;56(7):925–33.
28. Leder K, Torresi J, Brownstein JS, Wilson ME, Keystone JS,
Barnett E, et al. Travel-associated illness trends and clusters,
2000-2010. Emerg Infect Dis. 2013;19(7):1049–73.
29. Schwartz E, Weld LH, Wilder-Smith A, von Sonnenburg F,
Keystone JS, Kain KC, et al. Seasonality, annual trends, and char-
acteristics of dengue among ill returned travelers, 1997-2006.
Emerg Infect Dis. 2008;14(7):1081–8.
30. Masyeni S, Yohan B, Somia IKA, Myint KSA, Sasmono RT.
Dengue infection in international travellers visiting Bali,
Indonesia. J Travel Med. 2018;25(1).
31. Poddighe D, Bonomelli I, Giardinetti S, Nedbal M, Bruni P.
Paediatric dengue fever diagnosed through parents’ epidemiologic
report and preventive strategy during the acute phase of infection.
J Travel Med. 2016;23(1).
32. Rabinowicz S, Schwartz E. Morbidity among Israeli paediatric
travellers. J Travel Med. 2017;24(6).
33. Neuberger A, Turgeman A, Lustig Y, Schwartz E. Dengue fever
among Israeli expatriates in Delhi, 2015: implications for dengue
incidence in Delhi, India. J Travel Med. 2016;23(3).
34. Olivero RM, Hamer DH, MacLeod WB, Benoit CM, Sanchez-
Vegas C, Jentes ES, et al. Dengue virus seroconversion in travelers
to dengue-endemic areas. Am J Trop Med Hyg. 2016.
35.• Rocklov J, Lohr W, Hjertqvist M, Wilder-Smith A. Attack rates of
dengue fever in Swedish travellers. Scand J Infect Dis.
2014;46(6):412–7 Calculates attack rates, as both the numer-
ator and denominator are known.
36. Sanchez-Vegas C, Hamer DH, Chen LH, Wilson ME, Benoit C,
Hunsperger E, et al. Prevalence of dengue virus infection in US
travelers who have lived in or traveled to dengue-endemic coun-
tries. J Travel Med. 2013;20(6):352–60.
37. Loconsole D, Metallo A, De Robertis AL, Morea A, Quarto M,
Chironna M. Seroprevalence of dengue virus, West Nile virus,
chikungunya virus, and Zika virus in international travelers attend-
ing a travel and migration center in 2015-2017, Southern Italy.
Vector Borne Zoonotic Dis. 2018;18(6):331–4.
38. Ratnam I, Black J, Leder K, Biggs BA, Matchett E, Padiglione A,
et al. Incidence and seroprevalence of dengue virus infections in
Australian travellers to Asia. Eur J Clin Microbiol Infect Dis.
2012;31(6):1203–10.
39. Sohail A,McGuinness SL, Lightowler R, Leder K, JomonB, Bain
CA, et al. Spectrum of illness among returned Australian travellers
from Bali, Indonesia: a 5-year retrospective observational study.
Intern Med J. 2018.
40. Ferguson RW, Henderson SJ, Lee EA, Jung P. Dengue in peace
corps volunteers, 2000–14. J Travel Med. 2016;23(3).
41. Moncayo AC, Baumblatt J, Thomas D, Harvey KA, Atrubin D,
Stanek D, et al. Dengue among American missionaries returning
from Jamaica, 2012. Am J Trop Med Hyg. 2015;92(1):69–71.
42. Caci JB, Blaylock JM, De La Barrera R, Griggs AN, Lin L,
Jarman RG, et al. Seroprevalence of dengue fever in US Army
special operations forces: initial results and the way ahead. J Spec
Oper Med. 2014;14(3):111–5.
43. Chen LH, Leder K, Barbre KA, Schlagenhauf P, Libman M,
Keystone J, et al. Business travel-associated illness: a
GeoSentinel analysis. J Travel Med. 2018;25(1).
44.• Struchiner CJ, Rocklov J, Wilder-Smith A, Massad E. Increasing
dengue incidence in Singapore over the past 40 years: population
growth, climate and mobility. PLoS One. 2015;10(8):e0136286
Best evidence that population density is the main driver for
dengue resurgence.
45. Pavli A, Maltezou H. Health problems of newly arrived migrants
and refugees in Europe. J Travel Med. 2017;24(4).
46. Olanwijitwong J, Piyaphanee W, Poovorawan K, Lawpoolsri S,
Chanthavanich P, Wichainprasast P, et al. Health problems among
Thai tourists returning from India. J Travel Med. 2017;24(4).
47. Sadarangani SP, Lim PL, Vasoo S. Infectious diseases and migrant
worker health in Singapore: a receiving country's perspective. J
Travel Med. 2017;24(4).
48. Simkhada PP, Regmi PR, van Teijlingen E, Aryal N. Identifying
the gaps in Nepalese migrant workers’ health and well-being: a
review of the literature. J Travel Med. 2017;24(4).
49. Xu C, Pang J, Hsu JP, Leo YS, Lye DCB. Differences in clinical
features and dengue severity between local and migrant Chinese
with dengue infection in Singapore. PLoS One. 2018;13(8):
e0201441.
50. Seet RC, Ooi EE, Wong HB, Paton NI. An outbreak of primary
dengue infection among migrant Chinese workers in Singapore
characterized by prominent gastrointestinal symptoms and a high
proportion of symptomatic cases. J Clin Virol. 2005;33(4):336–
40.
51. Leder K, Tong S, Weld L, Kain KC, Wilder-Smith A, von
Sonnenburg F, et al. Illness in travelers visiting friends and rela-
tives: a review of the GeoSentinel Surveillance Network. Clin
Infect Dis. 2006;43(9):1185–93.
52. Rowe K, Chaves N, Leder K. Challenges to providing pre-travel
care for travellers visiting friends and relatives: an audit of a spe-
cialist travel medicine clinic. J Travel Med. 2017;24(5).
53. WHO. Dengue: guidelines for diagnosis, treatment, prevention
and control - New edition. Switzerland: World Health
Organization; 2009. 147 p
54. Lam PK, Tam DT, Diet TV, Tam CT, Tien NT, Kieu NT, et al.
Clinical characteristics of dengue shock syndrome in Vietnamese
children: a 10-year prospective study in a single hospital. Clin
Infect Dis. 2013;57(11):1577–86.
55. Rosenberger KD, Lum L, Alexander N, Junghanss T, Wills B,
Jaenisch T, et al. Vascular leakage in dengue–clinical spectrum
and influence of parenteral fluid therapy. Tropical Med Int
Health. 2016;21(3):445–53.
56. Halstead SB, Udomsakdi S, Simasthien P, Singharaj P,
Sukhavachana P, Nisalak A. Observations related to pathogenesis
of dengue hemorrhagic fever. I. Experience with classification of
dengue viruses. Yale J Biol Med. 1970;42(5):261–75.
57.•• Salje H, Cummings DAT, Rodriguez-Barraquer I, Katzelnick LC,
Lessler J, Klungthong C, et al. Reconstruction of antibody dynam-
ics and infection histories to evaluate dengue risk. Nature.
2018;557(7707):719–23 Best evidence on the impact of certain
antibody ratios that determine the risk of severe dengue.
58.•• Katzelnick LC, Gresh L, Halloran ME, Mercado JC, Kuan G,
Gordon A, et al. Antibody-dependent enhancement of severe den-
gue disease in humans. Science. 2017;358(6365):929–32 Best
evidence on the impact of certain antibody ratios that deter-
mine the risk of severe dengue.
59. Kobayashi K, Hikone M, Sakamoto N, Iwabuchi S, Kashiura M,
Takasaki T, et al. Dengue-associated hemophagocytic syndrome
in a Japanese traveler: a case report. J Travel Med. 2015;22(1):64–
6.
60. Zea D, Foley K, Carey J. Myocarditis in a traveler returning from
the Dominican Republic: an unusual presentation of dengue fever.
Am J Trop Med Hyg. 2014;91(1):156–8.
61. Kirawittaya T, Yoon IK, Wichit S, Green S, Ennis FA, Gibbons
RV, et al. Evaluation of cardiac involvement in children with den-
gue by serial echocardiographic studies. PLoS Negl Trop Dis.
2015;9(7):e0003943.
62. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B.
Cardiovascular manifestations of the emerging dengue pandemic.
Nat Rev Cardiol. 2014;11(6):335–45.
63. Ling LM,Wilder-Smith A, Leo YS. Fulminant hepatitis in dengue
haemorrhagic fever. J Clin Virol. 2007;38(3):265–8.
   50 Page 6 of 8 Curr Infect Dis Rep           (2018) 20:50 
64. Ng AW, Teoh SC. Dengue eye disease. Surv Ophthalmol.
2015;60(2):106–14.
65. Carod-Artal FJ, Wichmann O, Farrar J, Gascon J. Neurological
complications of dengue virus infection. Lancet Neurol.
2013;12(9):906–19.
66.• Wilder-Smith A, Chang CR, Leong WY. Zika in travellers 1947–
2017: a systematic review. J Travel Med. 2018;25(1). Review on
Zika in travelers.
67. Dalugama C, Shelton J, Ekanayake M, Gawarammana IB.
Dengue fever complicated with Guillain-Barre syndrome: a case
report and review of the literature. J Med Case Rep. 2018;12(1):
137.
68. Tang X, Zhao S, Chiu APY, Wang X, Yang L, He D. Analysing
increasing trends of Guillain-Barre syndrome (GBS) and dengue
cases in Hong Kong using meteorological data. PLoS One.
2017;12(12):e0187830.
69. Boo YL, Aris MAM, Chin PW, Sulaiman WAW, Basri H, Hoo
FK. Guillain-Barre syndrome complicating dengue fever: two
case reports. Ci Ji Yi Xue Za Zhi. 2016;28(4):157–9.
70. Vieira M, Cruz ACR, Barros ANM, Costa DL, Silva E, Batista
FMA, et al. Guillain-Barre syndrome and dengue-like disease in
2015: temporal relationship in Piaui state and implications on Zika
virus surveillance. Rev Inst Med Trop Sao Paulo. 2017;59:e22.
71. Fragoso YD, Gomes S, Brooks JB, Matta AP, Ruocco HH, Tauil
CB, et al. Guillain-Barre syndrome and dengue fever: report on ten
new cases in Brazil. Arq Neuropsiquiatr. 2016;74(12):1039–40.
72. Simon O, Billot S, Guyon D, Daures M, Descloux E, Gourinat
AC, et al. Early Guillain-Barre syndrome associated with acute
dengue fever. J Clin Virol. 2016;77:29–31.
73. Ralapanawa DM, Kularatne SA, JayalathWA.Guillain-Barre syn-
drome following dengue fever and literature review. BMC Res
Notes. 2015;8:729.
74. Lim M, Goh HK. Rhabdomyolysis following dengue virus infec-
tion. Singap Med J. 2005;46(11):645–6.
75. Shivanthan MC, Ratnayake EC, Wijesiriwardena BC, Somaratna
KC, Gamagedara LK. Paralytic squint due to abducens nerve pal-
sy: a rare consequence of dengue fever. BMC Infect Dis. 2012;12:
156.
76. Ramos JM, Tello A, Alzamora A, Ramon ML. Optic neuritis in a
traveler returning from Dominican Republic to Spain with dengue
virus infection. J Travel Med. 2015;22(2):133–5.
77. Kumar J, Kumar A, Gupta S, Jain D. Dengue haemorrhagic fever:
an unusual cause of intracranial haemorrhage. BMJ Case Rep.
2009;2009:bcr2006100909.
78. Verma R, Sahu R, Holla V. Neurological manifestations of dengue
infection: a review. J Neurol Sci. 2014;346(1–2):26–34.
79. Gautret P, Gaudart J, Leder K, Schwartz E, Castelli F, Lim PL,
et al. Travel-associated illness in older adults (> 60 y). J Travel
Med. 2012;19(3):169–77.
80. Flaherty GT, Rossanese A, Steffen R, Torresi J. A golden age of
travel: advancing the interests of older travellers. J Travel Med.
2018.
81. Pang J, Hsu JP, Yeo TW, Leo YS, Lye DC. Diabetes, cardiac
disorders and asthma as risk factors for severe organ involvement
among adult dengue patients: a matched case-control study. Sci
Rep. 2017;7:39872.
82. Pang J, Salim A, Lee VJ, Hibberd ML, Chia KS, Leo YS, et al.
Diabetes with hypertension as risk factors for adult dengue hem-
orrhagic fever in a predominantly dengue serotype 2 epidemic: a
case control study. PLoS Negl Trop Dis. 2012;6(5):e1641.
83. Willen SM, Thornburg CD, Lantos PM. Travelers with sickle cell
disease. J Travel Med. 2014;21(5):332–9.
84. Bich TD, Pham OK, Hai DH, Nguyen NM, Van HN, The TD,
et al. A pregnant woman with acute cardiorespiratory failure: den-
gue myocarditis. Lancet. 2015;385(9974):1260.
85. Hariyanto H, Yahya CQ, Wibowo P, Tampubolon OE.
Management of severe dengue hemorrhagic fever and bleeding
complications in a primigravida patient: a case report. J Med Case
Rep. 2016;10(1):357.
86. Basurko C, Matheus S, Hilderal H, Everhard S, Restrepo M,
Cuadro-Alvarez E, et al. Estimating the risk of vertical transmis-
sion of dengue: a prospective study. Am J Trop Med Hyg.
2018;98:1826–32.
87.•• Dengue vaccine: WHO position paper-September 2018. Wkly
Epidemiol Rec. 2018;93 457–76. Summarizes the characteris-
tics and safety issues of CYD-TDV.
88. Andries AC, Duong V, Ly S, Cappelle J, Kim KS, Lorn Try P,
et al. Value of routine dengue diagnostic tests in urine and saliva
specimens. PLoS Negl Trop Dis. 2015;9(9):e0004100.
89. Hunsperger EA, Yoksan S, Buchy P, Nguyen VC, Sekaran SD,
Enria DA, et al. Evaluation of commercially available diagnostic
tests for the detection of dengue virus NS1 antigen and anti-
dengue virus IgM antibody. PLoS Negl Trop Dis. 2014;8(10):
e3171.
90. Fuchs I, Bin H, Schlezinger S, Schwartz E. NS1 antigen testing for
the diagnosis of dengue in returned Israeli travelers. J Med Virol.
2014;86(12):2005–10.
91. van Meer MPA, Mogling R, Klaasse J, Chandler FD, Pas SD, van
der Eijk AA, et al. Re-evaluation of routine dengue virus serology
in travelers in the era of Zika virus emergence. J Clin Virol.
2017;92:25–31.
92. Tsai WY, Youn HH, Brites C, Tsai JJ, Tyson J, Pedroso C, et al.
Distinguishing secondary dengue virus infection from Zika virus
infection with previous dengue by a combination of 3 simple
serological tests. Clin Infect Dis. 2017;65(11):1829–36.
93. LeeYH, LeongWY,Wilder-Smith A.Markers of dengue severity:
a systematic review of cytokines and chemokines. J Gen Virol.
2016;97(12):3103–19.
94. Wilder-Smith A, Ooi EE, Horstick O, Wills B. Dengue. The
Lancet 2018; in print.
95. Piyaphanee W, Chanthavanich P. Residency training in travel
medicine-a 3-year journey to become a specialist. J Travel Med.
2016;23(5).
96. Flaherty G, Thong Zi Yi C, Browne R. The missing link: intro-
ducing travel medicine into the undergraduate medical curriculum.
J Travel Med. 2016;23(5).
97. Goodyer L, Schofield S.Mosquito repellents for the traveller: does
picaridin provide longer protection than DEET? J Travel Med.
2018;25(suppl_1):S10–S5.
98. Lalani T, Yun H, Tribble D, Ganesan A, Kunz A, Fairchok M,
et al. A comparison of compliance rates with anti-vectorial protec-
tive measures during travel to regions with dengue or chikungunya
activity, and regions endemic for Plasmodium falciparummalaria.
J Travel Med. 2016;23(5).
99. Orsborne J, DeRaedt Banks S, Hendy A, Gezan SA, Kaur H,
Wilder-Smith A, et al. Personal protection of permethrin-treated
clothing against Aedes aegypti, the vector of dengue and Zika
virus, in the laboratory. PLoS One. 2016;11(5):e0152805.
100. DeRaedt Banks S, Orsborne J, Gezan SA, Kaur H, Wilder-Smith
A, Lindsey SW, et al. Permethrin-treated clothing as protection
against the dengue vector, Aedes aegypti: extent and duration of
protection. PLoS Negl Trop Dis. 2015;9(10):e0004109.
101. Kittayapong P, Olanratmanee P, Maskhao P, Byass P, Logan J,
Tozan Y, et al. Mitigating diseases transmitted by Aedes mosqui-
toes: a cluster-randomised trial of permethrin-impregnated school
uniforms. PLoS Negl Trop Dis. 2017;11(1):e0005197.
102. Ritchie SA.Wolbachia and the near cessation of dengue outbreaks
in northern Australia despite continued dengue importations via
travellers. J Travel Med. 2018.
103. Wilder-Smith A. Dengue vaccines for travelers: has the time
come? J Travel Med. 2015;22(3):200–2.
Curr Infect Dis Rep           (2018) 20:50 Page 7 of 8    50 
104. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C,
Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term
safety of a dengue vaccine in regions of endemic disease. N
Engl J Med. 2015;373(13):1195–206.
105. Sridhar S, Luedtke A, Langevin E, Zhu M, Bonaparte M,
Machabert T, et al. Effect of dengue serostatus on dengue vaccine
safety and efficacy. N Engl J Med. 2018;379:327–40.
106. Wilder-Smith A. Four-year safety follow-up of the tetravalent
dengue vaccine CYD-TDV. Clin Microbiol Infect. 2018;24:
680–1.
107.•• Wilder-Smith A. Serostatus-dependent performance of the first
licensed dengue vaccine: implications for travellers. J Travel
Med. 2018;25(1). Critically analyses the serostatus-dependent
performance of CYD-TDV dengue vaccine, and the implica-
tions for travelers.
108. Arien KK,Wilder-Smith A. Dengue vaccine: reliably determining
previous exposure. Lancet Glob Health. 2018;6:e830–1.
109. Hadinegoro SR, Arredondo-Garcia JL, Capeding MR, Deseda C,
Chotpitayasunondh T, Dietze R, et al. Efficacy and long-term
safety of a dengue vaccine in regions of endemic disease. N
Engl J Med. 2015.
110. Torresi J, Steffen R. Redefining priorities towards graded travel-
related infectious disease research. J Travel Med. 2017;24(6).
   50 Page 8 of 8 Curr Infect Dis Rep           (2018) 20:50 
